| Surgical outcomes of patients with gastrointestinal stromal tumors in the era of targeted drug therapy. | |
| | |
MedLine Citation:
|
PMID: 18546049 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
BACKGROUND: The discovery of the c-KIT mutation and the advent of targeted drug therapy with imatinib mesylate have revolutionized the management of gastrointestinal stromal tumors (GISTs). The outcome of patients with surgically treated GISTs treated in the era of targeted drug therapy was assessed and factors associated with adverse outcomes determined. MATERIALS AND METHODS: Patients with GISTs requiring surgery at a tertiary care center from 2002 to 2007 were reviewed and prognostic factors determined. RESULTS: Forty patients were surgically treated for GISTs. The median age at presentation was 59 years. The stomach (55%) was the main site of primary disease. The median tumor size was 7 cm. Eleven (28%) patients had metastatic disease at presentation. Surgery was undertaken in all patients with curative intent. Multi-organ resection was required in 10 (25%) patients. Imatinib mesylate was administered postoperatively in 68% of cases. Median follow-up was 24 months. There was a 40% recurrence rate with 63% undergoing repeat surgical resection. The peritoneum and liver were the main sites of recurrent disease. The 5-year disease-specific survival and disease-free survival (DFS) were 65% and 35%, respectively. High mitotic rate (P = 0.017) and tumor size greater than 10 cm (P = 0.009) were the only prognostically significant adverse factors of DFS on multivariate analysis, independent of imatinib mesylate treatment. CONCLUSION: Aggressive surgical treatment and follow-up of GISTs, combined with targeted drug therapy, leads to long-term DFS survival. Tumor recurrence is independently associated with a high tumor mitotic rate and size greater than 10 cm, despite the use of adjuvant targeted drug therapy. |
| | |
Authors:
|
Mehrdad Nikfarjam; Eric Kimchi; Serene Shereef; Niraj J Gusani; Yixing Jiang; John Liang; Mandeep Sehmbey; Kevin F Staveley-O'Carroll |
Related Documents
:
|
23599789 - Safety and efficacy of panitumumab therapy after metastatic colorectal cancer progressi... 9115449 - Chronic lymphocytic leukemia in the elderly population. 6983869 - Immunologic status of children with hodgkin's disease (hd). 18055869 - The prognostic significance of a positive direct antiglobulin test in chronic lymphocyt... 17315159 - Treatment of chronic myeloid leukemia in the imatinib era: perspective from a developin... 15203279 - Modified vad and psc-833 in the treatment of resistant or relapsing chronic lymphocytic... 15333859 - Survival and disease progression in uk patients with lymphangioleiomyomatosis. 7532059 - Combined chemotherapy and granulocyte colony-stimulating factor (g-csf) mobilise large ... 20847419 - Executive function predicts survival in alzheimer disease: a study in shanghai. |
Publication Detail:
|
Type: Comparative Study; Journal Article Date: 2008-06-11 |
Journal Detail:
|
Title: Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract Volume: 12 ISSN: 1873-4626 ISO Abbreviation: J. Gastrointest. Surg. Publication Date: 2008 Nov |
Date Detail:
|
Created Date: 2008-10-22 Completed Date: 2009-02-11 Revised Date: 2009-11-19 |
Medline Journal Info:
|
Nlm Unique ID: 9706084 Medline TA: J Gastrointest Surg Country: United States |
Other Details:
|
Languages: eng Pagination: 2023-31 Citation Subset: IM |
Affiliation:
|
Department of Surgery, Penn State College of Medicine, Penn State Milton S. Hershey Medical Center, H070, 500 University Drive, P.O. Box 850, Hershey, PA 17033-0850, USA. mnikfarjam@psu.edu |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Aged Chemotherapy, Adjuvant Cohort Studies Disease-Free Survival Dose-Response Relationship, Drug Drug Administration Schedule Drug Delivery Systems Female Follow-Up Studies Gastrointestinal Stromal Tumors / drug therapy*, mortality, pathology, surgery* Humans Immunohistochemistry Male Middle Aged Neoplasm Staging Piperazines / administration & dosage* Probability Proportional Hazards Models Proto-Oncogene Proteins c-kit / drug effects*, genetics Pyrimidines / administration & dosage* Retrospective Studies Risk Assessment Statistics, Nonparametric Survival Analysis Treatment Outcome |
| Chemical | |
Reg. No./Substance:
|
0/Piperazines; 0/Pyrimidines; 152459-95-5/imatinib; EC 2.7.10.1/Proto-Oncogene Proteins c-kit |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Episode-based physician profiling: a guide to the perplexing.
Next Document: Pseudotumors after primary abdominal lipectomy as a new sequela in patients with abdominal apron.